NASDAQ · LNSR

LENSAR, Inc.

$5.37 -$0.23 (-4.11%) 1D Market open

Key Metrics

$68.78M
Market cap
1.08×
P/E · TTM
−$731.00K
Revenue · TTM
$63.68M
Net income
EPS · TTM $5.41
Dividend yield
Free cash flow
Beta · 1Y 0.48
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 24
    From its Jan 30 high, the share price fell 60%.

    Peak close $12.73 on Jan 30; trough close $5.09 on Apr 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -60%
  • Mar 17
    The stock moved -32.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 17
  • Mar 13
    The stock moved -15.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 13

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$68.78M
Enterprise value
Shares outstanding12.3M
52-wk range$5.06 – $13.32
Avg volume · 20D45.7K
Net cash
Book value / share$0.92
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About LENSAR, Inc.
IPO dateSep 21, 2020
Employees150

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E1.08
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №$10.56

Profitability

Gross
Operating -1,098.4%
Net -8,710.9%
FCF
ROE / ROIC 590.1% · —

Financial Health

Current ratio2.38
Quick ratio1.08
Debt / equity
Debt / EBITDA
Net cash
Working capital$24.60M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-1.2
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$10.56 vs $5.37
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings